Sol-Gel Technologies’ (SLGL) Buy Rating Reiterated at HC Wainwright

Sol-Gel Technologies (NASDAQ:SLGLGet Rating)‘s stock had its “buy” rating restated by HC Wainwright in a report issued on Monday, TipRanks reports. They currently have a $20.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 178.16% from the stock’s current price.

Several other research analysts have also weighed in on the company. Zacks Investment Research raised Sol-Gel Technologies from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Wednesday, April 6th. Raymond James dropped their price objective on Sol-Gel Technologies from $21.00 to $17.00 and set a “strong-buy” rating on the stock in a report on Friday, April 1st.

SLGL traded up $0.65 on Monday, reaching $7.19. 856 shares of the company traded hands, compared to its average volume of 13,504. The company has a market cap of $146.60 million, a price-to-earnings ratio of 55.31 and a beta of 1.17. The stock’s 50 day moving average price is $7.36 and its 200-day moving average price is $7.83. Sol-Gel Technologies has a 52-week low of $6.12 and a 52-week high of $15.31.

Sol-Gel Technologies (NASDAQ:SLGLGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.40 by $0.21. Sol-Gel Technologies had a net margin of 10.30% and a return on equity of 7.03%. On average, sell-side analysts anticipate that Sol-Gel Technologies will post -0.62 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Susquehanna International Group LLP lifted its holdings in Sol-Gel Technologies by 34.0% in the 4th quarter. Susquehanna International Group LLP now owns 16,862 shares of the company’s stock worth $125,000 after purchasing an additional 4,275 shares during the last quarter. Raymond James & Associates raised its position in shares of Sol-Gel Technologies by 14.1% in the third quarter. Raymond James & Associates now owns 36,608 shares of the company’s stock valued at $365,000 after purchasing an additional 4,519 shares during the period. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Sol-Gel Technologies by 6.2% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 129,011 shares of the company’s stock worth $1,288,000 after buying an additional 7,544 shares during the last quarter. Finally, We Are One Seven LLC bought a new stake in shares of Sol-Gel Technologies during the 4th quarter worth $74,000. 28.79% of the stock is currently owned by institutional investors and hedge funds.

Sol-Gel Technologies Company Profile (Get Rating)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.

Further Reading

Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.